Sandy Spring Bank Exact Sciences Corp Transaction History

Sandy Spring Bank

$2.33 Billion
Q1 2025

A detailed history of Sandy Spring Bank transactions in Exact Sciences Corp stock. As of the latest transaction made, Sandy Spring Bank holds 1,600 shares of EXAS stock, worth $111,344. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,600

Previous 1,600 -0.0%

Holding current value

$111,344

Previous $89,000 22.47%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	SELL	$42.43 - $70.83 $4,752 - $7,932	-112 Reduced 6.54%	1,600 $108,000
Q1 2024 May 08, 2024	SELL	$56.27 - $73.77 $32,917 - $43,155	-585 Reduced 25.47%	1,712 $118,000
Q1 2022 May 03, 2022	SELL	$57.56 - $82.54 $17,268 - $24,762	-300 Reduced 11.55%	2,297 $161,000
Q4 2021 Feb 11, 2022	SELL	$72.5 - $100.68 $580 - $805	-8 Reduced 0.31%	2,597 $203,000
Q4 2020 Feb 03, 2021	SELL	$99.61 - $142.12 $49,008 - $69,923	-492 Reduced 15.89%	2,605 $345,000
Q2 2020 Aug 12, 2020	BUY	$55.75 - $92.75 $5,407 - $8,996	97 Added 3.23%	3,097 $269,000
Q1 2020 May 01, 2020	SELL	$37.9 - $104.44 $568 - $1,566	-15 Reduced 0.5%	3,000 $174,000
Q4 2019 Feb 06, 2020	BUY	$77.66 - $99.74 $39,994 - $51,366	515 Added 20.6%	3,015 $278,000
Q2 2019 Aug 01, 2019	SELL	$89.51 - $118.04 $18,797 - $24,788	-210 Reduced 7.75%	2,500 $295,000
Q2 2018 Aug 03, 2018	SELL	$37.84 - $69.96 $74,242 - $137,261	-1,962 Reduced 41.99%	2,710 $162,000
Q1 2018 May 04, 2018	BUY	$39.82 - $57.53 $62,198 - $89,861	1,562 Added 50.23%	4,672 $188,000
Q4 2017 Feb 02, 2018	SELL	$46.49 - $60.51 $18,131 - $23,598	-390 Reduced 11.14%	3,110 $163,000
Q2 2017 Aug 11, 2017	BUY	N/A	3,500	3,500 $124,000

Others Institutions Holding EXAS

# of Institutions

656

Shares Held

158M

Call Options Held

1.43M

Put Options Held

2.35M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12.3B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.

Account

Sandy Spring Bank Exact Sciences Corp Transaction History